DNA Vaccine Market
DNA Vaccine Market Size, Share & Trends Analysis By Type (Animal DNA Vaccine and Human DNA Vaccine), By Technology (Plasmid DNA Vaccines Technology and Plasmid DNA Delivery Technology), By Application (Oncology, Infectious Diseases, and Others), Forecast Period (2026-2035)
Industry Overview
DNA vaccine market was valued at $960 million in 2025 and is projected to reach $1,475 million by 2035, growing at a CAGR of 4.5% during the forecast Period (2026-2035). The market is growing due to factors such as increased R&D investment, technological advancements, and the rising prevalence of infectious diseases and cancer. Other drivers include the demand for personalized medicine, the need for vaccines with easier storage and transportation, and supportive regulatory environments.
Market Dynamics
Technological Advancements in Delivery and Manufacturing
One of the key drivers of the global DNA vaccine market is the significant improvement in vaccine delivery methods and plasmid manufacturing technologies. Historically, DNA vaccines faced challenges related to low immunogenicity and inefficient in vivo delivery. The development of advanced electroporation devices, optimized adjuvants, and high-yield, GMP-compliant plasmid production has improved vaccine efficacy and scalability. These innovations allow faster clinical translation and greater commercial feasibility, thereby accelerating market growth.
Rising Investment and Regulatory Support Post-Pandemic
The COVID-19 pandemic highlighted the rapid development potential of nucleic acid-based vaccines, including DNA platforms. This led to increased investments from governments, venture capital, and pharmaceutical companies, alongside greater regulatory attention and streamlined approval pathways for emergency use and clinical trials. The enhanced funding and supportive regulatory environment are driving accelerated R&D programs, partnerships, and collaborations in the DNA vaccine space, which continues to fuel market expansion.
Expansion into Therapeutic and Veterinary Applications
Another major market driver is the diversification of DNA vaccine applications beyond traditional infectious diseases. Therapeutic DNA vaccines for oncology and approved veterinary DNA vaccines, such as the Oncept canine melanoma vaccine, are opening new revenue streams. This broader application scope reduces dependency on a single segment, attracts more commercial investment, and increases the overall adoption of DNA vaccine technologies across human and animal health markets.
Market Segmentation
- Based on the type, the market is segmented into animal DNA vaccines and human DNA vaccines.
- Based on the technology, the market is segmented into Plasmid DNA vaccine technology and plasmid DNA delivery technology.
- Based on the application, the market is segmented into oncology, infectious diseases, and others.
Infectious Diseases Segment to Grow at a Considerable Market Share
The infectious diseases segment under the application category is expected to lead the market with the largest share. This dominance is driven by the expanding global burden of infectious diseases, the rising emergence of viral outbreaks, and the growing adoption of DNA vaccine platforms for rapid, safe, and scalable immunization. DNA vaccines offer strong immunogenicity, ease of development, and high stability, making them ideal for combating infectious agents such as influenza, Zika, HIV, and emerging pathogens. Additionally, increased R&D funding, accelerated regulatory pathways, and successful advances in DNA-based immunotherapies further strengthen the segment’s leadership, positioning infectious diseases as the largest and fastest-growing application area within the global DNA vaccine market.
Plasmid DNA Vaccines Technology: A Key Segment in Market Growth
The plasmid DNA vaccines technology segment is projected to emerge as the key driver of market growth over the forecast period. This technology has garnered significant attention due to its ability to stimulate robust immune responses while ensuring safety and stability, which are critical factors for both human and veterinary applications. Plasmid DNA vaccines offer advantages such as ease of design, rapid production timelines, and the flexibility to target multiple antigens, making them highly suitable for combating emerging infectious diseases and pandemics. The increasing focus on advanced therapeutic solutions for infectious diseases, cancer, and genetic disorders has further fueled demand for plasmid-based vaccines.
Additionally, ongoing innovations in molecular biology, genetic engineering, and delivery mechanisms enhance the efficacy and market adoption of plasmid DNA vaccines. Key factors driving this growth include supportive regulatory frameworks, rising investments by pharmaceutical and biotechnology companies, and growing awareness about the benefits of DNA-based immunisation over traditional vaccines. As a result, Plasmid DNA Vaccines Technology is expected to dominate the DNA vaccine landscape, capturing a substantial share of market growth and playing a pivotal role in shaping the future of preventive and therapeutic vaccine solutions globally.
Regional Outlook
The global DNA vaccine market is further divided by geography, including North America (the US and Canada), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), and the Rest of the World (the Middle East & Africa, and Latin America).
North America Region to Hold a Substantial Growth Rate
North America, particularly the US, dominates the global DNA vaccine market, holding a major share due to its advanced biotechnology infrastructure, substantial R&D investment, and strong presence of key industry players. The country benefits from a robust ecosystem of vaccine research, including both public and private sector initiatives, with significant government funding from agencies such as the NIH, BARDA, and CEPI, which actively support the development of next-generation nucleic acid vaccines. In addition, the US has a well-established clinical trial network and advanced regulatory frameworks that enable faster approval and commercialization of innovative DNA vaccine candidates. Companies like Inovio Pharmaceuticals, Moderna, Dynavax, and VGXI are headquartered or operate major facilities in the US, driving both technological advancements and manufacturing capacity for plasmid-based DNA vaccines. The country’s dominance is further reinforced by ongoing investments in pandemic preparedness, cancer immunotherapy, and other therapeutic areas where DNA vaccines are showing promise. While Asia-Pacific and Europe are growing rapidly, the US continues to lead in market size, clinical activity, and technological innovation, establishing itself as the global hub for DNA vaccine development and commercialisation. This stronghold enables the US to influence global market trends, partnerships, and adoption of DNA vaccine platforms across both human and veterinary applications.
Market Players Outlook
The major companies operating in the global DNA vaccine market include GlaxoSmithKline plc, Merck and Co., Pfizer Inc., and Roche Diagnostics, among others. Market players are leveraging partnerships, collaborations, mergers, and acquisitions to expand their businesses and develop innovative products to maintain their market positioning.
Recent Development
- In July 2025, Inovio Pharmaceuticals dosed the first participant in a Phase?2 trial of its DNA vaccine candidate against MERS (Middle East Respiratory Syndrome). This is part of a program backed by CEPI, with plans to eventually create a stockpile for emergency use if trials succeed.
- In March 2025, BioNTech collaborated with Regeneron Pharmaceuticals to co?develop plasmid?based DNA vaccines for emerging infectious diseases.
- In January 2025, Inovio collaborated with Johnson & Johnson to advance a pipeline of DNA vaccine candidates targeting infectious diseases and cancer, combining development and manufacturing capabilities.
The Report Covers
- Market value data analysis for 2025 and forecast to 2035.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global DNA vaccine market. Based on the availability of data, information related to new products and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
- Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Global DNA Vaccine Market Sales Analysis – Type | Technology | Technology ($ Million)
- DNA Vaccine Market Sales Performance of Top Countries
- Research Methodology
- Primary Research Approach
- Secondary Research Approach
- Market Snapshot
- Market Overview and Insights
- Scope of the Study
- Analyst Insight & Current Market Trends
- Key DNA Vaccine Market Trends
- Market Recommendations
- Market Determinants
- Market Drivers
- Drivers For Global DNA Vaccine Market: Impact Analysis
- Market Pain Points and Challenges
- Restraints For Global DNA Vaccine Market: Impact Analysis
- Market Opportunities
- Opportunities For Global DNA Vaccine Market: Impact Analysis
- Market Drivers
- Competitive Landscape
- Competitive Dashboard – DNA Vaccine Market Revenue and Share by Manufacturers
- DNA Vaccine Product Comparison Analysis
- Top Market Player Ranking Matrix
- Key Company Analysis
- GlaxoSmithKline plc
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Roche Diagnostics
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Pfizer Inc.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Merck & Co., Inc.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Top Winning Strategies by Market Players
- Merger and Acquisition
- Product Launch
- Partnership And Collaboration
- GlaxoSmithKline plc
- Key Company Analysis
- Global DNA Vaccine Market Sales Analysis by Type ($ Million)
- Animal DNA Vaccine
- Human DNA Vaccine
- Global DNA Vaccine Market Sales Analysis by Technology ($ Million)
- Plasmid DNA Vaccines Technology
- Plasmid DNA Delivery Technology
- Global DNA Vaccine Market Sales Analysis by Technology ($ Million)
- Oncology
- Infectious Diseases
- Others
- Regional Analysis
- North American DNA Vaccine Market Sales Analysis – Type | Technology | Technology | Country ($ Million)
- Macroeconomic Factors for North America
- United States
- Canada
- European DNA Vaccine Market Sales Analysis – Type | Technology | Technology | Country ($ Million)
- Macroeconomic Factors for Europe
- UK
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia-Pacific DNA Vaccine Market Sales Analysis – Type | Technology | Technology | Country ($ Million)
- Macroeconomic Factors for Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia & New Zealand
- ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
- Rest of Asia-Pacific
- Rest of the World DNA Vaccine Market Sales Analysis – Type | Technology | Technology | Country ($ Million)
- Macroeconomic Factors for the Rest of the World
- Latin America
- Middle East and Africa
- Company Profiles
- Applied DNA Sciences, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Astellas Pharma, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Boehringer Ingelheim GmbH
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Eli Lilly and Company (Novartis Animal Health)
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Entos Pharmaceuticals, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- GeneOne Life Science, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Genexine, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- GeoVax Labs, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- GlaxoSmithKline (GSK) Plc
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Inovio Pharmaceuticals, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Merck & Co., Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Pfizer Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Sanofi S.A.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Takara Holdings (Takara Bio)
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Takis Biotech S.r.l.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- VGXI, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Viatris Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Vical, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Zoetis Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Zydus Cadila Ltd. (Cadila Healthcare)
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Applied DNA Sciences, Inc.
1. Global DNA Vaccine Market Research and Analysis by Type, 2025–2035 ($ Million)
2. Global Animal DNA Vaccine Market Research And Analysis By Region, 2025–2035 ($ Million)
3. Global Human DNA Vaccine Market Research And Analysis By Region, 2025–2035 ($ Million)
4. Global DNA Vaccine Market Research and Analysis by Technology, 2025–2035 ($ Million)
5. Global Plasmid DNA Vaccines Technology Market Research And Analysis By Region, 2025–2035 ($ Million)
6. Global Plasmid DNA Delivery Technology Market Research And Analysis By Region, 2025–2035 ($ Million)
7. Global DNA Vaccine Market Research and Analysis by Application, 2025–2035 ($ Million)
8. Global DNA Vaccine In Oncology Market Research And Analysis By Region, 2025–2035 ($ Million)
9. Global DNA Vaccine In Infectious Diseases Market Research And Analysis By Region, 2025–2035 ($ Million)
10. Global DNA Vaccine In Other Application Market Research And Analysis By Region, 2025–2035 ($ Million)
11. Global DNA Vaccine Market Research and Analysis by Region, 2025–2035 ($ Million)
12. North American DNA Vaccine Market Research and Analysis by Country, 2025–2035 ($ Million)
13. North American DNA Vaccine Market Research and Analysis by Type, 2025–2035 ($ Million)
14. North American DNA Vaccine Market Research and Analysis by Technology, 2025–2035 ($ Million)
15. North American DNA Vaccine Market Research and Analysis by Application, 2025–2035 ($ Million)
16. North American DNA Vaccine Market Research and Analysis by End User, 2025–2035 ($ Million)
17. European DNA Vaccine Market Research and Analysis by Country, 2025–2035 ($ Million)
18. European DNA Vaccine Market Research and Analysis by Type, 2025–2035 ($ Million)
19. European DNA Vaccine Market Research and Analysis by Technology, 2025–2035 ($ Million)
20. European DNA Vaccine Market Research and Analysis by Application, 2025–2035 ($ Million)
21. European DNA Vaccine Market Research and Analysis by End User, 2025–2035 ($ Million)
22. Asia-Pacific DNA Vaccine Market Research and Analysis by Country, 2025–2035 ($ Million)
23. Asia-Pacific DNA Vaccine Market Research and Analysis by Type, 2025–2035 ($ Million)
24. Asia-Pacific DNA Vaccine Market Research and Analysis by Technology, 2025–2035 ($ Million)
25. Asia-Pacific DNA Vaccine Market Research and Analysis by Application, 2025–2035 ($ Million)
26. Asia-Pacific DNA Vaccine Market Research and Analysis by End User, 2025–2035 ($ Million)
27. Rest of the World DNA Vaccine Market Research and Analysis by Region, 2025–2035 ($ Million)
28. Rest of the World DNA Vaccine Market Research and Analysis by Type, 2025–2035 ($ Million)
29. Rest of the World DNA Vaccine Market Research and Analysis by Technology, 2025–2035 ($ Million)
30. Rest of the World DNA Vaccine Market Research and Analysis by Application, 2025–2035 ($ Million)
31. Rest of the World DNA Vaccine Market Research and Analysis by End User, 2025–2035 ($ Million)
1. Global DNA Vaccine Market Share By Type, 2025 Vs 2035 (%)
2. Global Animal DNA Vaccine Market Share By Region, 2025 Vs 2035 (%)
3. Global Human DNA Vaccine Market Share By Region, 2025 Vs 2035 (%)
4. Global DNA Vaccine Market Share Analysis by Technology, 2025 VS 2035 (%)
5. Global Plasmid DNA Vaccines Technology Market Share By Region, 2025 Vs 2035 (%)
6. Global Plasmid DNA Delivery Technology Market Share By Region, 2025 Vs 2035 (%)
7. Global DNA Vaccine Market Share Analysis by Application, 2025 VS 2035 (%)
8. Global DNA Vaccine In Oncology Market Share By Region, 2025 Vs 2035 (%)
9. Global DNA Vaccine In Infectious Diseases Market Share By Region, 2025 Vs 2035 (%)
10. Global DNA Vaccine In Other Application Market Share By Region, 2025 Vs 2035 (%)
11. Global DNA Vaccine Market Share By Region, 2025 Vs 2035 (%)
12. US DNA Vaccine Market Size, 2025–2035 ($ Million)
13. Canada DNA Vaccine Market Size, 2025–2035 ($ Million)
14. UK DNA Vaccine Market Size, 2025–2035 ($ Million)
15. France DNA Vaccine Market Size, 2025–2035 ($ Million)
16. Germany DNA Vaccine Market Size, 2025–2035 ($ Million)
17. Italy DNA Vaccine Market Size, 2025–2035 ($ Million)
18. Spain DNA Vaccine Market Size, 2025–2035 ($ Million)
19. Russia DNA Vaccine Market Size, 2025–2035 ($ Million)
20. Rest of Europe DNA Vaccine Market Size, 2025–2035 ($ Million)
21. India DNA Vaccine Market Size, 2025–2035 ($ Million)
22. China DNA Vaccine Market Size, 2025–2035 ($ Million)
23. Japan DNA Vaccine Market Size, 2025–2035 ($ Million)
24. South Korea DNA Vaccine Market Size, 2025–2035 ($ Million)
25. Australia and New Zealand DNA Vaccine Market Size, 2025–2035 ($ Million)
26. ASEAN Economies DNA Vaccine Market Size, 2025–2035 ($ Million)
27. Rest of Asia-Pacific DNA Vaccine Market Size, 2025–2035 ($ Million)
28. Latin America DNA Vaccine Market Size, 2025–2035 ($ Million)
29. Middle East and Africa DNA Vaccine Market Size, 2025–2035 ($ Million)
- Printable version
- No restriction to number of users within the company
